Fortrea Announces Updated Presentation Time at Upcoming J.P. Morgan Healthcare Conference
Globe Newswire (Fri, 9-Jan 11:24 AM ET)
Fortrea to Present at Upcoming J.P. Morgan Healthcare Conference
Globe Newswire (Tue, 6-Jan 7:00 AM ET)
Globe Newswire (Tue, 16-Dec 8:40 AM ET)
Globe Newswire (Fri, 12-Dec 2:37 PM ET)
Globe Newswire (Thu, 11-Dec 9:39 AM ET)
Fortrea Awards 245,000 RSUs to New Hires as Part of Strategic Talent Acquisition Plan
Market Chameleon (Thu, 11-Dec 3:33 AM ET)
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Wed, 10-Dec 6:00 PM ET)
Globe Newswire (Mon, 8-Dec 8:35 AM ET)
Market Chameleon (Thu, 4-Dec 5:17 AM ET)
Globe Newswire (Thu, 4-Dec 7:00 AM ET)
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
Fortrea Holdings trades on the NASDAQ stock market under the symbol FTRE.
As of January 13, 2026, FTRE stock price declined to $18.07 with 113,499 million shares trading.
FTRE has a beta of 1.30, meaning it tends to be more sensitive to market movements. FTRE has a correlation of 0.05 to the broad based SPY ETF.
FTRE has a market cap of $1.67 billion. This is considered a Small Cap stock.
Last quarter Fortrea Holdings reported $701 million in Revenue and $.12 earnings per share. This beat revenue expectation by $59 million and missed earnings estimates by -$.04.
The top ETF exchange traded funds that FTRE belongs to (by Net Assets): IJR, IWM, VTI, FNDA, IJS.
FTRE has underperformed the market in the last year with a return of -0.7%, while SPY returned +20.6%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in FTRE shares. However, FTRE has outperformed the market in the last 3 month and 2 week periods, returning +86.8% and +4.8%, while SPY returned +6.4% and +0.8%, respectively. This indicates FTRE has been having a stronger performance recently.
FTRE support price is $17.63 and resistance is $19.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FTRE shares will trade within this expected range on the day.